Recent Patents on CNS Drug Discovery (Discontinued)

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078
Italy

Back

Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?

Author(s): Henrik Zetterberg

Affiliation: Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital/Molndal, S-431 80 Molndal, Sweden.

Abstract:

Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-β (Aβ42) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimers disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the clinical routine and in clinical trials, there is a strong interest in the possible association of Aβ levels in plasma with AD. This review provides an update on the current status of research on plasma Aβ as a biomarker for AD in the context of recent patents in the field.

Keywords: Plasma, Amyloid beta, Alzheimer's disease, Mild cognitive impairment, Biomarker

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 3
ISSUE: 2
Page: [109 - 111]
Pages: 3
DOI: 10.2174/157488908784534595
Price: $100